Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Cytotoxic chemotherapy
10 evidence topics · 10 sources
Guideline summary of chemotherapy in metastatic uveal melanoma
“Response rates are low (<10%) regardless of the cytotoxic agent tested and whether it was used as monotherapy or in combination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drugs evaluated in this setting include dacarbazine, temozolomide, treosulfan, cisplatin and fotemustine” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“with no demonstrated OS benefit over best supportive care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled response to systemic treatment across 40 studies of 841 evaluable participants
“Complete or partial remissions were observed in 39/841 patients (overall response rate [ORR] 4.6%; 95% confidence intervals [CI] 3.3–6.3%), no responses were observed in 22/40 studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MUM is frequently treated with chemotherapeutics like dacarbazine, fotemustine, or gemcitabine/treosulfan although evidence for these regimens is limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Temozolomide or dacarbazine as the control arm of a randomized phase 2 trial of selumetinib
“Randomized open-label phase II clinical trial comparing selumetinib versus chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“101 patients were randomized on a 1:1 ratio to selumetinib 75 mg orally twice daily on a continual basis (n=50) or chemotherapy (temozolomide 150 mg/m2 orally daily for 5 of every 28 days or DTIC 1000 mg/m2 intravenously every 21 days; investigator choice; n=51) until disease progression, death, intolerable toxicity, or withdrawal of consent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median progression-free survival for those randomized to chemotherapy and selumetinib was 7 (95% CI, 4.3 – 8.4; median treatment duration of 8 weeks (IQR, 4.3–16)) and 15.9 weeks (95% CI, 8.4 – 21.1; median treatment duration of 16.1 weeks (IQR, 8.1–25.3)), respectively (hazard ratio 0.46; 95% CI, 0.30 – 0.71; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median overall survival was 9.1 (95% CI, 6.1 – 11.1) and 11.8 months (95% CI, 9.8 – 15.7) for those randomized to chemotherapy and selumetinib, respectively (hazard ratio 0.66; 95% CI, 0.41–1.06; p=0.09).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No objective responses were observed with chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Temozolomide or dacarbazine versus cabozantinib: randomized phase 2 Alliance A091201 trial
“Alliance for Clinical Trials in Oncology A091201, a randomized phase II trial of the multiple TKI cabozantinib that also inhibits MET and VEGFR2 compared with temozolomide (TMZ) or dacarbazine (DTIC) in patients with metastatic UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with metastatic UM and RECIST measurable disease were randomized 2:1 to receive either cabozantinib (arm 1) versus temozolomide or dacarbazine (arm 2) with restaging imaging every two cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rates of PFS4 in arm 1 and arm 2 were 32.3% and 26.7% (p=0.35), respectively, with median PFS time of 60 and 59 days (p=0.964; HR=0.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median overall survival was 6.4 months and 7.3 months (p=0.580; HR=1.21), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3–4 CTCAE adverse events were present in 61.3%, 46.7%, and 37.5% in arms 1, 2 and 2X, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MET/VEGFR blockade with cabozantinib demonstrated no improvement in PFS but an increase in toxicity relative to temozolomide/dacarbazine in metastatic UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Objective response with placebo plus dacarbazine compared with selumetinib plus dacarbazine
Intravenous versus hepatic intra-arterial fotemustine: randomized phase 3 EORTC 18021 trial
“The prospective randomized phase III trial (EORTC 18021) thus aimed to compare the efficacy and safety of HIA versus IV fotemustine in UM patients with metastases in liver only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Accrual was stopped after randomization of 171 patients based on the results of a futility OS analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HIA did not improve OS (median 14.6 months) when compared with the IV arm (median 13.8 months), hazard ratio (HR) 1.09; 95% confidence interval (CI) 0.79–1.50, log-rank P = 0.59.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, there was a significant benefit on PFS for HIA compared with IV with a median of 4.5 versus 3.5 months, respectively (HR 0.62; 95% CI 0.45–0.84, log-rank P = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An improved RR was seen in the HIA (10.5%) compared with IV treatment (2.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The main grade ≥3 toxicity related to HIA was catheter complications (12%) and liver toxicity (4.5%) apart from two toxic deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Temozolomide: phase 2 trial of 14 participants with liver metastases
“we conducted a phase II clinical trial of temozolomide in patients with uveal melanoma metastatic to the liver.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fourteen patients were enrolled in the trial.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No complete or partial responses were observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We conclude that, like DTIC, temozolomide at the dose and schedule studied in this trial is not effective for the control of metastatic melanoma of uveal origin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Temozolomide plus bevacizumab: noncomparative phase 2 study of 36 participants
“This noncomparative phase II study evaluated a combination of bevacizumab (10 mg/kg on days 8 and 22) with temozolomide (150 mg/m 2 on days 1–7 and 15–21) in 36 patients with metastatic uveal melanoma (MUM).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median PFS and OS were 12 weeks and 10 months, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with MUM, a combination of bevacizumab plus temozolomide achieved a 6-month PFR of 23%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cisplatin, dacarbazine, and vinblastine as first-line treatment for unresectable metastases: phase 2 study
“In the present phase II study we administered intravenously cisplatin (80 mg/mq, day 1), dacarbazine (250 mg/mq/day, days 1-3), vinblastine (2 mg maximum, day 1) every 21 days as first line treatment for patients with unresectable metastases of uveal melanoma and BRAF wild type.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Partial responses were observed in five (20%) patients, stable disease in 12 (48%) patients; disease control rate was 68%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS of all the patients was 13 months, median progression free survival was 5.5 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Five (20%) patients experienced grade 3-4 toxicity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Chemotherapy in the control group of a randomized trial of isolated hepatic perfusion
“In the control group, 49% received chemotherapy, 39% immune checkpoint inhibitors, and 9% locoregional treatment other than IHP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These disappointing outcomes reflect generally poor responses to systemic chemotherapy, which shows minimal efficacy and delivers no detectable survival benefit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote